Preparation and identification of a 9B9 monoclonal antibody specifically targeting EGFRvIII/EGFR

Chinese Journal of Cancer Biotherapy

Volumn 16, Issue 4, 2009, Pages 391-395

  Gao, Hui Ping ^a   Jiang, Hua ^a   Wang, Hua Mao ^a   Li, Zong Hai ^a  

^a Shanghai Cancer Center   (China)

Author keywords

Epidemal growth factor receptor variant type III (EGFRvIII); Epidermal growth factor receptor (EGFR); Epidermal neoplasms; Hepatocellular neoplasms; Monoclonal antibody

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 9B9; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BAGG ALBINO MOUSE; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOFLUORESCENCE TEST; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; SKIN CARCINOMA; SPLEEN CELL; WESTERN BLOTTING;

EID: 77951256768     PISSN: 1007385X     EISSN: None     Source Type: Journal    
DOI: 10.3872/j.issn.1007-385X.2009.04.015     Document Type: Article

References (21)

1. Ullrich A, Coussens L, Hayflick JS, et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells [J]. Nature, 1984,309(5967):418-425. (Pubitemid 14102443)
2. Modjtahedi H, Dean C. The receptor for EGF and its ligands expression, prognostic value and target for therapy in cancer [J]. Int J Oncol, 1994,4(1):277-296. (Pubitemid 24039840)
3. Kuan CT, Wikstrand CJ, Bigner DD. EGF mutant receptor vIII as a molecular target in cancer therapy [J]. Endocr Relat Cancer, 2001,8(2):83-96. (Pubitemid 32641351)
4. Diedrich U, Lucius J, Baron E, et al. Distribution of epidermal growth factor receptor gene amplification in brain tumours and correlation to prognosis [J]. J Neurol, 1995,242(10):683-688.
5. Feldkamp MM, Lala P, Lau N, et al. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens [J]. Neurosurgery, 1999,45(6):1442-1453.
6. Pedersen NW, Meltorn M, Damstrup L, et al. The type III epidermal growth factor receptor mutation [J]. Ann Oncol, 2001,12(6):745-760.
7. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy [J]. Oncologist, 2002,7(4):2-8. (Pubitemid 34977157)
8. Scott AM, Lee FT, Tebbutt N, et al. A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors [J]. Proc Natl Acad Sci USA, 2007,104(10):4071-4076. (Pubitemid 47181580)
9. Fury MG, Lipton A, Smith KM, et al. A phase-I trial of the epidermal growth factor directed bipecific antibody MDX-447 without and with recombinant human granulocyte-colony stimulating factor in patients with advanced solid tumors [J]. Cancer Immunol Immun, 2008,57(2):155-163. (Pubitemid 350159917)
10. Ou C, Wu FX, Luo Y, et al. Expression and significance of epidermal growth factor receptor variant type III in hepatocellular carcinoma [J]. J Chin Cancer, 2005,24(2):166-169.
11. Bode U, Buchen S, Janssen G, et al. Results of a phase II trial of h-R3 monoclonal antibody (nimotuzumab) in the treatment of resistant or relaped high-grade gliomas in children and asolecents [J]. J Clin Oncol, 2006,24(18S):1522-1528.
12. Peeters M, Cutserm VE, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer [J]. J Clin Oncol, 2007,25(13):1658-1664. (Pubitemid 46797944)
13. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck [J]. N Engl J Med, 2006,354(6):567-578. (Pubitemid 43209104)
14. Food KA, Yang XD, Weiner LM, et al. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody [J]. Int J Radiat Oncol Biol Phys, 2004,58(3):984-990.
15. Rocha-Lima CM, Soares HP, Raez LE, et al. EGFR targeting of solid tumors [J]. Cancer Control, 2007,14(3):295-304.
16. Overman MJ, Hoff PM. EGFR-targeting therapies in colorectal cancer [J]. Dis Colon Rectum, 2007,50(8):1259-1270.
17. Wang HM, Jiang H, Li ZH, et al. Epidermal growth factor receptor vIII enhances tumorigenicity and resistance to 5-fluorouracil in human hepatocellular carcinoma [J]. Cancer Lett, 2009,279(1):30-38.
18. Liu CM, Liu DP, Dong WJ, et al. Retrovirus vector-mediated stable gene silenceing in human cell [J]. Biochem Biophys Res Commun, 2004,313(3):716-720.
19. Burtness B. The role of cetuximab in the treatment of squamous cell of head and neck [J]. Expert Opin Biol Ther, 2005,5(8):1085-1093. (Pubitemid 41170037)
20. Harding J, Burtness B. Cetuximab: an epidermal growth factor chemeric human-murine monoclonal antibody [J]. Drugs Today (Barc), 2005,41(2):107-127. (Pubitemid 40461533)
21. Huether A, Hopfner M, Baradari V, et al. EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer [J]. Biochem Pharmacol, 2005,70(11):1568-1578. (Pubitemid 41540350)